Second Orphan Drug Designation for VibeX for Corneal Ectasia

Avedro announced that the FDA has granted a second orphan drug designation for VibeX (riboflavin ophthalmic solution) for use with its KXL System (UVA irradiation) for corneal cross-linking to treat corneal ectasia following refractive surgery, such as Lasik and photorefractive keratectomy. Avedro has also received orphan drug designation for cross-linking for the treatment of keratoconus.

VibeX is Avedro’s proprietary riboflavin (vitamin B2) used in conjunction with Avedro’s KXL System. VibeX is topically applied to the cornea after epithelium removal and allowed to diffuse into the corneal stroma. UV light from the KXL system is applied to the eye which activates the VibeX in the stroma resulting in cornea strengthening.

For more information, call (781) 768-3400 or visit www.avedro.com.